-0.04 | -0.57%
| Price and Volume | |
|---|---|
| Recent Price | 6.96 |
| 52 Week High | 9.71 |
| 52 Week Low | 4.07 |
| Avg. Daily Vol. (Mil) | 1.25 |
| Beta (3 year) | 1.64 |
| Share Related Items | |
| Mkt Cap (Mil) | 797.69 |
| Shares Out (Mil) | 114.61 |
| Float (Mil) | 91.05 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.50 |
| Current Ratio | 1.60 |
| LT Debt/ Equity | 0.09 |
| Total Debt / Equity | 1.41 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 10.21 |
| Price/Book | 4.91 |
| Price/Cash Flow | -6.40 |
| Per Share Data | |
| Earnings | -1.22 |
| Sales | 0.68 |
| Book Value | 1.42 |
| Cash Flow | -1.09 |
| Business Summary | |
|---|---|
| Nektar Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PE Gylation and polymer conjugate technology platforms. | |
| General Information | |
| 455 Mission Bay Boulevard So
San Francisco, CA 94158 |
|
| www.nektar.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 423 | |
| CEO: Mr. Howard W. Robin | |
| Short Interest | |
| Current Month (Mil) | 19.66 |
| Previous Month (Mil) | 20.54 |
| Short Interest Ratio (Days) | 20.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -20.00 |
| Return on Investments | -78.00 |
| Profitability | |
| Gross Margin | 83.70 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
106.76
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet